Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 35OTHER 33NIH 8NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Head & Neck 1Dermatologic 1

Conditions

Melanoma 1Brain Neoplasms 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Radiotherapy 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Etoposide 3Cyclophosphamide 3Cisplatin 3Watchful Waiting 2Vincristine 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Introns 2Interferon alpha-2 2Immunologic Techniques 2Flow Cytometry 2Carboplatin 2trametinib 1tebentafusp 1sulforaphane 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × dabrafenib × Dermatologic × Clear all
NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡